Literature DB >> 32309036

Immediate reactions with glatiramer acetate: Diagnosis of allergy and desensitization protocols.

Guadalupe Marco-Martín1, Pilar Tornero1, Alicia Prieto1, Alejandro La Rotta1, Teresa Herrero1, Maria Luisa Baeza1.   

Abstract

PURPOSE OF REVIEW: Diverse adverse events have been associated with administration of glatiramer acetate (GA), mainly local reactions at the injection site. Other, less frequent generalized reactions include isolated postinjection reactions and anaphylaxis, which may lead to discontinuation of GA. RECENT
FINDINGS: Close collaboration between the allergy and neurology departments is needed to study adverse reactions to GA. The allergy study should include a detailed history and skin prick and intradermal tests with GA and, if possible, determination of specific IgE levels. Furthermore, the implication of other drugs should be ruled out.
SUMMARY: An accurate diagnosis of reactions to GA is essential if we are to confirm or rule out allergy to GA. When an allergy diagnosis is confirmed or firmly suspected based on clinical evidence, desensitization protocols are increasingly seen as safe methods for reintroduction of GA.
© 2019 American Academy of Neurology.

Entities:  

Year:  2020        PMID: 32309036      PMCID: PMC7156204          DOI: 10.1212/CPJ.0000000000000714

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  21 in total

1.  Modified protocol for desensitization to glatiramer acetate.

Authors:  Shashank S Sheth; Mark A Posner
Journal:  Ann Allergy Asthma Immunol       Date:  2010-07-03       Impact factor: 6.347

2.  Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Aaron Boster; Mary Pat Bartoszek; Colleen O'Connell; David Pitt; Michael Racke
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

3.  IgE-mediated allergic reactions after the first administration of glatiramer acetate in patients with multiple sclerosis.

Authors:  Mercè Corominas; Idoia Postigo; Victoria Cardona; Ramon Lleonart; Lucía Romero-Pinel; Jorge Martinez
Journal:  Int Arch Allergy Immunol       Date:  2015-01-29       Impact factor: 2.749

4.  IgE-mediated hypersensitivity reaction and desensitization to glatiramer acetate in a pediatric patient.

Authors:  E Crestani; J Lee; M Gorman; M Castells; A F Dioun Broyles
Journal:  Pediatr Allergy Immunol       Date:  2014-10-16       Impact factor: 6.377

5.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

Review 6.  Glatiramer acetate for multiple sclerosis.

Authors:  Loredana La Mantia; Luca M Munari; Roberta Lovati
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

7.  Allergy workup in immediate-type local reactions to glatiramer acetate.

Authors:  J Sánchez-López; P Rodríguez del Rio; B Cases-Ortega; C Martínez-Cócera; M Fernández-Rivas
Journal:  J Investig Allergol Clin Immunol       Date:  2010       Impact factor: 4.333

8.  Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization.

Authors:  Rebecca G Breslow; Joana Caiado; Mariana C Castells
Journal:  Ann Allergy Asthma Immunol       Date:  2009-02       Impact factor: 6.347

Review 9.  Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.

Authors:  Dean M Wingerchuk
Journal:  Expert Rev Neurother       Date:  2006-03       Impact factor: 4.618

10.  Clinical features and severity grading of anaphylaxis.

Authors:  Simon G A Brown
Journal:  J Allergy Clin Immunol       Date:  2004-08       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.